Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia: Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989
The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium...
Gespeichert in:
| Weitere beteiligte Personen: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | Englisch |
| Veröffentlicht: |
Boston, MA
Springer US
1990
|
| Schriftenreihe: | Developments in Cardiovascular Medicine
112 |
| Schlagwörter: | |
| Links: | https://doi.org/10.1007/978-1-4613-1505-6 https://doi.org/10.1007/978-1-4613-1505-6 |
| Zusammenfassung: | The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect |
| Umfang: | 1 Online-Ressource (X, 230 p) |
| ISBN: | 9781461315056 |
| DOI: | 10.1007/978-1-4613-1505-6 |
Internformat
MARC
| LEADER | 00000nam a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046146354 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s1990 xx o|||| 00||| eng d | ||
| 020 | |a 9781461315056 |9 978-1-4613-1505-6 | ||
| 024 | 7 | |a 10.1007/978-1-4613-1505-6 |2 doi | |
| 035 | |a (ZDB-2-SME)978-1-4613-1505-6 | ||
| 035 | |a (OCoLC)1118995181 | ||
| 035 | |a (DE-599)BVBBV046146354 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.12 |2 23 | |
| 245 | 1 | 0 | |a Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia |b Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 |c edited by Joel Morganroth, E. Neil Moore |
| 246 | 1 | 3 | |a Proceedings of the Tenth Annual Symposium on New Drugs and Devices, October 31-November 1, 1989 |
| 264 | 1 | |a Boston, MA |b Springer US |c 1990 | |
| 300 | |a 1 Online-Ressource (X, 230 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Developments in Cardiovascular Medicine |v 112 | |
| 520 | |a The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect | ||
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Cardiology | |
| 650 | 0 | 7 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antihypertonikum |0 (DE-588)4002286-9 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)1071861417 |a Konferenzschrift |y 1989 |z Philadelphia Pa. |2 gnd-content | |
| 689 | 0 | 0 | |a Antihypertonikum |0 (DE-588)4002286-9 |D s |
| 689 | 0 | 1 | |a Arzneimittelprüfung |0 (DE-588)4128030-1 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Morganroth, Joel |4 edt | |
| 700 | 1 | |a Moore, E. Neil |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461288091 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780792307563 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461315063 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4613-1505-6 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031526539 | |
| 966 | e | |u https://doi.org/10.1007/978-1-4613-1505-6 |l DE-355 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1818986032194912256 |
|---|---|
| any_adam_object | |
| author2 | Morganroth, Joel Moore, E. Neil |
| author2_role | edt edt |
| author2_variant | j m jm e n m en enm |
| author_facet | Morganroth, Joel Moore, E. Neil |
| building | Verbundindex |
| bvnumber | BV046146354 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-1-4613-1505-6 (OCoLC)1118995181 (DE-599)BVBBV046146354 |
| dewey-full | 616.12 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.12 |
| dewey-search | 616.12 |
| dewey-sort | 3616.12 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-1-4613-1505-6 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04070nam a2200541zcb4500</leader><controlfield tag="001">BV046146354</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s1990 xx o|||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781461315056</subfield><subfield code="9">978-1-4613-1505-6</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4613-1505-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-1-4613-1505-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1118995181</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046146354</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.12</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia</subfield><subfield code="b">Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989</subfield><subfield code="c">edited by Joel Morganroth, E. Neil Moore</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Proceedings of the Tenth Annual Symposium on New Drugs and Devices, October 31-November 1, 1989</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 230 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Developments in Cardiovascular Medicine</subfield><subfield code="v">112</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cardiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antihypertonikum</subfield><subfield code="0">(DE-588)4002286-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1989</subfield><subfield code="z">Philadelphia Pa.</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antihypertonikum</subfield><subfield code="0">(DE-588)4002286-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelprüfung</subfield><subfield code="0">(DE-588)4128030-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morganroth, Joel</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Moore, E. Neil</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461288091</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780792307563</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461315063</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4613-1505-6</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031526539</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4613-1505-6</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)1071861417 Konferenzschrift 1989 Philadelphia Pa. gnd-content |
| genre_facet | Konferenzschrift 1989 Philadelphia Pa. |
| id | DE-604.BV046146354 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T18:44:20Z |
| institution | BVB |
| isbn | 9781461315056 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031526539 |
| oclc_num | 1118995181 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 230 p) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 1990 |
| publishDateSearch | 1990 |
| publishDateSort | 1990 |
| publisher | Springer US |
| record_format | marc |
| series2 | Developments in Cardiovascular Medicine |
| spelling | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 edited by Joel Morganroth, E. Neil Moore Proceedings of the Tenth Annual Symposium on New Drugs and Devices, October 31-November 1, 1989 Boston, MA Springer US 1990 1 Online-Ressource (X, 230 p) txt rdacontent c rdamedia cr rdacarrier Developments in Cardiovascular Medicine 112 The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect Cardiology Arzneimittelprüfung (DE-588)4128030-1 gnd rswk-swf Antihypertonikum (DE-588)4002286-9 gnd rswk-swf 1\p (DE-588)1071861417 Konferenzschrift 1989 Philadelphia Pa. gnd-content Antihypertonikum (DE-588)4002286-9 s Arzneimittelprüfung (DE-588)4128030-1 s 2\p DE-604 Morganroth, Joel edt Moore, E. Neil edt Erscheint auch als Druck-Ausgabe 9781461288091 Erscheint auch als Druck-Ausgabe 9780792307563 Erscheint auch als Druck-Ausgabe 9781461315063 https://doi.org/10.1007/978-1-4613-1505-6 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 Cardiology Arzneimittelprüfung (DE-588)4128030-1 gnd Antihypertonikum (DE-588)4002286-9 gnd |
| subject_GND | (DE-588)4128030-1 (DE-588)4002286-9 (DE-588)1071861417 |
| title | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 |
| title_alt | Proceedings of the Tenth Annual Symposium on New Drugs and Devices, October 31-November 1, 1989 |
| title_auth | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 |
| title_exact_search | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 |
| title_full | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 edited by Joel Morganroth, E. Neil Moore |
| title_fullStr | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 edited by Joel Morganroth, E. Neil Moore |
| title_full_unstemmed | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 edited by Joel Morganroth, E. Neil Moore |
| title_short | Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia |
| title_sort | use and approval of antihypertensive agents and surrogate endpoints for the approval of drugs affecting antiarrhythmic heart failure and hypolipidemia proceedings of the tenth annual symposium on new drugs devices october 31 november 1 1989 |
| title_sub | Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989 |
| topic | Cardiology Arzneimittelprüfung (DE-588)4128030-1 gnd Antihypertonikum (DE-588)4002286-9 gnd |
| topic_facet | Cardiology Arzneimittelprüfung Antihypertonikum Konferenzschrift 1989 Philadelphia Pa. |
| url | https://doi.org/10.1007/978-1-4613-1505-6 |
| work_keys_str_mv | AT morganrothjoel useandapprovalofantihypertensiveagentsandsurrogateendpointsfortheapprovalofdrugsaffectingantiarrhythmicheartfailureandhypolipidemiaproceedingsofthetenthannualsymposiumonnewdrugsdevicesoctober31november11989 AT mooreeneil useandapprovalofantihypertensiveagentsandsurrogateendpointsfortheapprovalofdrugsaffectingantiarrhythmicheartfailureandhypolipidemiaproceedingsofthetenthannualsymposiumonnewdrugsdevicesoctober31november11989 AT morganrothjoel proceedingsofthetenthannualsymposiumonnewdrugsanddevicesoctober31november11989 AT mooreeneil proceedingsofthetenthannualsymposiumonnewdrugsanddevicesoctober31november11989 |